Apyx Medical Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Apyx Medical Corporation (NASDAQ:APYX) has granted a nonstatutory stock option to John Featherstone, the company's Vice President of North American Sales, as part of his employment inducement. The stock option allows for the purchase of 100,000 shares of common stock at an exercise price of $1.85 per share, based on the closing price on August 4, 2025.
The stock option features a four-year vesting schedule, with 25% of shares vesting on the first anniversary and the remainder vesting annually thereafter, contingent upon continued employment. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as 搁别苍耻惫颈辞苍庐 and AYON Body Contouring System鈩� for cosmetic surgery, and 闯-笔濒补蝉尘补庐 for hospital surgical applications.
Apyx Medical Corporation (NASDAQ:APYX) ha concesso un'opzione azionaria non statutaria a John Featherstone, Vicepresidente delle Vendite per il Nord America, come parte di un incentivo lavorativo. L'opzione consente l'acquisto di 100.000 azioni ordinarie a un prezzo di esercizio di 1,85 $ per azione, basato sul prezzo di chiusura del 4 agosto 2025.
L'opzione prevede un programma di maturazione quadriennale, con il 25% delle azioni maturate al primo anniversario e il resto maturato annualmente successivamente, subordinato alla continuazione dell'impiego. Apyx Medical 猫 specializzata in tecnologia energetica avanzata, in particolare nella sua tecnologia Helium Plasma Platform, commercializzata come 搁别苍耻惫颈辞苍庐 e AYON Body Contouring System鈩� per la chirurgia estetica, e 闯-笔濒补蝉尘补庐 per applicazioni chirurgiche ospedaliere.
Apyx Medical Corporation (NASDAQ:APYX) ha otorgado una opci贸n sobre acciones no estatutaria a John Featherstone, vicepresidente de ventas para Norteam茅rica, como parte de un incentivo laboral. La opci贸n permite la compra de 100,000 acciones ordinarias a un precio de ejercicio de $1.85 por acci贸n, basado en el precio de cierre del 4 de agosto de 2025.
La opci贸n tiene un calendario de adquisici贸n de derechos de cuatro a帽os, con el 25% de las acciones adquiridas en el primer aniversario y el resto anualmente despu茅s, condicionado a la continuidad del empleo. Apyx Medical se especializa en tecnolog铆a avanzada de energ铆a, particularmente en su tecnolog铆a Helium Plasma Platform, comercializada como 搁别苍耻惫颈辞苍庐 y AYON Body Contouring System鈩� para cirug铆a est茅tica, y 闯-笔濒补蝉尘补庐 para aplicaciones quir煤rgicas hospitalarias.
Apyx Medical Corporation (NASDAQ:APYX)電� 攵侂 鞓侅梾 攵�靷灔鞚� John Featherstone鞐愱矊 瓿犾毄 鞙犾澑毂呾潣 鞚柬櫂鞙茧 牍勲矔鞝� 欤检嫕 鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�. 鞚� 欤检嫕 鞓奠厴鞚� 2025雲� 8鞗� 4鞚� 膦呹皜毳� 旮办鞙茧 欤茧嫻 1.85雼煬鞚� 頄夓偓 臧�瓴╈溂搿� 100,000欤�鞚� 氤错喌欤茧ゼ 甑Г頃� 靾� 鞛堧姅 甓岆Μ毳� 鞝滉车頃╇媹雼�.
欤检嫕 鞓奠厴鞚� 4雲勱皠鞚� 氩犾姢韺� 鞚检爼鞚� 韸轨鞙茧 頃橂┌, 觳� 氩堨Ц 旮半厫鞚检棎 25%臧� 氩犾姢韺呺悩瓿� 鞚错泟 毵る厔 雮橂ǜ歆� 欤检嫕鞚� 氩犾姢韺呺悩氅�, 瓿勳啀 瓿犾毄 臁瓣贝鞚� 於╈”霅橃柎鞎� 頃╇媹雼�. Apyx Medical鞚� 觳嫧 鞐愲剤歆� 旮办垹, 韸鬼瀳 氙胳毄 靾橃垹鞖� 搁别苍耻惫颈辞苍庐 氚� AYON Body Contouring System鈩㈥臣 氤戩洂 靾橃垹鞖� 闯-笔濒补蝉尘补庐搿� 韺愲Г霅橂姅 項エ 頂岆澕歃堧 頂岆灚韽� 旮办垹鞐� 鞝勲頇旊悩鞏� 鞛堨姷雼堧嫟.
Apyx Medical Corporation (NASDAQ:APYX) a accord茅 une option d'achat d'actions non statutaire 脿 John Featherstone, vice-pr茅sident des ventes pour l'Am茅rique du Nord, dans le cadre d'une incitation 脿 l'emploi. Cette option permet l'achat de 100 000 actions ordinaires au prix d'exercice de 1,85 $ par action, bas茅 sur le cours de cl么ture du 4 ao没t 2025.
L'option comprend un calendrier d'acquisition de droits sur quatre ans, avec 25 % des actions acquises au premier anniversaire, le reste 茅tant acquis annuellement par la suite, sous r茅serve de la poursuite de l'emploi. Apyx Medical est sp茅cialis茅e dans les technologies 茅nerg茅tiques avanc茅es, notamment sa technologie Helium Plasma Platform, commercialis茅e sous les noms 搁别苍耻惫颈辞苍庐 et AYON Body Contouring System鈩� pour la chirurgie esth茅tique, ainsi que 闯-笔濒补蝉尘补庐 pour les applications chirurgicales hospitali猫res.
Apyx Medical Corporation (NASDAQ:APYX) hat John Featherstone, dem Vice President f眉r Nordamerika-Vertrieb, im Rahmen eines Besch盲ftigungsanreizes eine nichtstatutarische Aktienoption gew盲hrt. Die Option erlaubt den Kauf von 100.000 Stammaktien zu einem Aus眉bungspreis von 1,85 $ pro Aktie, basierend auf dem Schlusskurs vom 4. August 2025.
Die Aktienoption beinhaltet einen Vesting-Zeitraum von vier Jahren, wobei 25 % der Aktien am ersten Jahrestag vesten und der Rest j盲hrlich danach, vorausgesetzt die Besch盲ftigung wird fortgesetzt. Apyx Medical ist auf fortschrittliche Energietechnologie spezialisiert, insbesondere auf die Helium Plasma Platform Technology, die als 搁别苍耻惫颈辞苍庐 und AYON Body Contouring System鈩� f眉r kosmetische Chirurgie sowie als 闯-笔濒补蝉尘补庐 f眉r chirurgische Anwendungen im Krankenhaus vermarktet wird.
- Appointment of new Vice President of North American Sales indicates focus on sales growth
- Stock option grant aligns executive interests with shareholder value through performance-based compensation
- Significant equity dilution potential from 100,000 share option grant
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (鈥淎pyx Medical鈥�; the 鈥淐ompany鈥�) today announced that on August 4, 2025, Apyx granted a nonstatuatory stock option to purchase 100,000 shares of common stock to John Featherstone, Apyx鈥檚 Vice President, North American Sales as a material inducement to such employee鈥檚 employment and in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price of
About Apyx Medical Corporation:
Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people鈥檚 lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion庐 and now the AYON Body Contouring System鈩⑻齣n the cosmetic surgery market and J-Plasma庐 in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical documents. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at . To learn more about how Renuvion or AYON can address loose skin concerns, and find a provider near you, visit or .
Cautionary Statement on Forward-Looking Statements:
Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.
All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to, projections of net revenue, margins, expenses, net earnings, net earnings per share, or other financial items; projections or assumptions concerning the possible receipt by the Company of any regulatory approvals from any government agency or instrumentality including but not limited to the U.S. Food and Drug Administration (the 鈥淔DA鈥�), supply chain disruptions, component shortages, manufacturing disruptions or logistics challenges; or macroeconomic or geopolitical matters and the impact of those matters on the Company鈥檚 financial performance.
Forward-looking statements and information are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company鈥檚 ability to control or predict. Important factors that may cause the Company鈥檚 actual results to differ materially and that could impact the Company and the statements contained in this release include but are not limited to risks, uncertainties and assumptions relating to the regulatory environment in which the Company is subject to, including the Company鈥檚 ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally; sudden or extreme volatility in commodity prices and availability, including supply chain disruptions; changes in general economic, business or demographic conditions or trends; changes in and effects of the geopolitical environment; liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations; and other risks that are described in the Company鈥檚 Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the Company鈥檚 other filings with the Securities and Exchange Commission. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Jeremy Feffer, Managing Director LifeSci Advisors
OP: 212-915-2568
听
FAQ
What stock options did Apyx Medical (NASDAQ:APYX) grant to its new VP of North American Sales?
What is the vesting schedule for the APYX stock options granted on August 4, 2025?
What are Apyx Medical's main product lines?
Who is John Featherstone at Apyx Medical?
